Seller record · Telehealth service

MaxLife

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the home page, the product pages or the terms. 1 more criterion also fails; see the table below.

At a glance

MaxLifeTelehealth service

6/8criteria passed
Price
Semaglutide $89 a month for the first 3 months, then $155; tirzepatide $120, then $195
Sells
compounded semaglutide, compounded tirzepatide
FDA letters
1 on file
Visit MaxLifeSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth platform selling compounded semaglutide and tirzepatide memberships with the medication, supplies and shipping included, working with independent physicians and medical groups. Care starts with a free consultation, it names ten partner pharmacies, and an FDA warning letter names its operating company.

Operating entity MaxLife Technologies Inc.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSMaxLife's website; MaxLife's terms of service page
S2Prescription gatingPASSMaxLife's website; MaxLife's compounded semaglutide page
S3Pharmacy identificationPASSMaxLife's website
S4Compounding disclosurePASSMaxLife's website; MaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page
S5Analytical documentationFAILMaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page; MaxLife's terms of service page
S6Business addressFAILMaxLife's terms of service page; MaxLife's privacy notice; MaxLife's website
S7Price disclosurePASSMaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page; MaxLife's website
S8Enforcement statusPASSFDA's website; FDA warning letter 721453

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSEvery prescription is reviewed by a licensed provider who monitors the dose, the answers say a provider holds a video visit where the state requires one, and the terms describe independent physicians and medical groups who may decline treatment.Source: MaxLife's website; MaxLife's terms of service page.
S2PASSThe home and product pages list a free consultation and health questions as the first step, before a provider approves and the prescription ships, and the home page says there is no upfront payment.Source: MaxLife's website; MaxLife's compounded semaglutide page.
S3PASSThe answers name the partner pharmacies that may prepare and dispense a prescription, depending on the patient's state: Dirx Pharmacy, Southend Pharmacy, Hallendale Pharmacy, Red Rock Pharmacy, Advanced Pharmacy, Perfect Rx Pharmacy, Health Wealth Pharmacy, Quaker Community Pharmacy, VLS Pharmacy and NewLife Rx Pharmacy.Source: MaxLife's website.
S4PASSThe footer of every page states that compounded medications are not subject to pre-market review or FDA approval, and the product pages say the study results for the brand-name drugs have not been established for the compounded versions.Source: MaxLife's website; MaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page.
S5FAILNo certificate of analysis or lot document is published on the home page, the product pages or the terms.Source: MaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page; MaxLife's terms of service page.
S6FAILThe terms and the privacy notice name MaxLife Technologies Inc., and the terms refer to a mailing address in a contact section they do not contain; no postal address appears in the footer, the terms or the privacy notice. The terms name California law.Source: MaxLife's terms of service page; MaxLife's privacy notice; MaxLife's website.
S7PASSCompounded semaglutide at an introductory Starter Kit price of $89 a month for 3 months, billed $267 up front, then $155 a month on the monthly plan. Compounded tirzepatide at $120 a month for 3 months, billed $360 up front, then $195 a month. Medication, supplies and shipping are included.Source: MaxLife's compounded semaglutide page; MaxLife's compounded tirzepatide page; MaxLife's website.
S8PASSFDA warning letter 721453, February 2026, names MaxLife Technologies Inc. doing business as Maxlife at an Irvine, California address the site itself does not publish, and it reviewed the seller's own website. It alleges that pictured labels identify Maxlife as the compounder of its semaglutide and tirzepatide products when it is not, and that claims such as FDA Approved present the compounded products as FDA-approved. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 721453.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatide

Enforcement documents on file: 1 warning letter

FDA warning letter 721453, issued February 2026, to MaxLife Technologies Inc. dba MaxlifePictured labels identify Maxlife as the compounder of semaglutide and tirzepatide products when it is not, and claims such as FDA Approved represent the compounded products as FDA-approved when they are not.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit MaxLife

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.